Continuum Advisory, LLC Xenon Pharmaceuticals Inc. Transaction History
Continuum Advisory, LLC
- $660 Million
- Q1 2024
A detailed history of Continuum Advisory, LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Continuum Advisory, LLC holds 15 shares of XENE stock, worth $552. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15Holding current value
$552% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding XENE
# of Institutions
228Shares Held
69MCall Options Held
307KPut Options Held
68.9K-
Avoro Capital Advisors LLC New York, NY5.67MShares$209 Million2.94% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.32MShares$159 Million2.04% of portfolio
-
Wellington Management Group LLP Boston, MA3.92MShares$144 Million0.03% of portfolio
-
Capital World Investors Los Angeles, CA2.68MShares$98.7 Million0.02% of portfolio
-
Polar Capital Holdings PLC London, X02.61MShares$96.2 Million0.7% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.29B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...